Alimera Sciences Signs Agreement With Quintiles for European Commercial Launch of ILUVIEN®

Alimera Sciences Signs Agreement With Quintiles for European Commercial Launch
                                 of ILUVIEN®

PR Newswire

ATLANTA, Dec. 4, 2012

ATLANTA, Dec. 4, 2012 /PRNewswire/ --Alimera Sciences, Inc., (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced it has signed a Master Services Agreement with Quintiles
Commercial Europe Ltd. (Quintiles) for the commercial launch of ILUVIEN^® in
certain European countries. ILUVIEN is Alimera's product for the treatment of
chronic diabetic macular edema considered insufficiently responsive to
available therapies.

"We believe this strategic collaboration with Quintiles will be pivotal in
achieving a successful launch of ILUVIEN in Europe, and at the outset, our
initial launch market of Germany," said Dan Myers, president and chief
executive officer, Alimera. "Quintiles' broad track-record in the
implementation and execution of multi-country, European commercialization
projects made the organization an ideal services provider for Alimera in
support of the commercial launch of ILUVIEN in Europe."

Services provided by Quintiles under the Master Services Agreement may include
marketing, brand management, sales promotion and detailing, market access,
regulatory, medical science liaison and communications and advisory services
in certain European countries. Under this agreement, Alimera and Quintiles
will enter into individual project orders that will specify the services to be

The German Project Order, the first under the Master Services Agreement, was
signed November 28, 2012. Under this project order, Quintiles Commercial
Germany GmbH will provide services related to recruitment, employment,
deployment and administration of the ILUVIEN commercialization team in Germany
through December 31, 2015. Alimera and Quintiles expect to sign additional
project orders for similar services in the United Kingdom and France.
Quintiles began interviewing and hiring personnel in Germany, the United
Kingdom and France in September in anticipation of the execution of project
orders in all three countries.

"This relationship leverages Quintiles' core commercial talent and strengths.
In addition, as the healthcare landscape has become more complex, it is
increasingly important to engage with multiple stakeholders across the patient
pathway. We have the broad expertise and experience to make this happen," said
Chris Pepler, senior vice president, Commercial Solutions at Quintiles. "As
Alimera Sciences enters these critical markets, we are excited to partner with
them to help drive the success of ILUVIEN in the European ophthalmic market."

About Quintiles

Quintiles is the world's leading provider of biopharmaceutical services. With
a network of more than 27,000 professionals working in more than 80 countries,
Quintiles has helped develop or commercialize all of the top 50 best selling
drugs on the market. With extensive therapeutic, scientific and analytics
expertise, Quintiles helps biopharmaceutical and health sciences customers
navigate the increasingly complex landscape with more predictability to enable
better outcomes.


ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in
applicator) is a sustained release intravitreal implant used to treat vision
impairment associated with chronic DME considered insufficiently responsive to
available therapies. Each ILUVIEN implant provides a therapeutic effect of up
to 36 months by delivering sustained sub-microgram levels of fluocinolone
acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a
position that takes advantage of the eye's natural fluid dynamics. The
applicator employs a 25-gauge needle, which allows for a self-sealing wound.
In the FAME Study, the most frequently reported adverse drug reactions
included cataract operation, cataract and increased ocular pressure.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to
seven European countries via the Decentralized Procedure (DCP) with the
Medicines and Healthcare products Regulatory Agency of the U.K. (MHRA) serving
as the Reference Member State (RMS). The MAA included data from two Phase 3
pivotal clinical trials (collectively known as the FAME Study) for ILUVIEN
conducted by Alimera. The trials involved 956 patients in sites across the
United States, Canada, Europe and India to assess the efficacy and safety of
ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was
reached by the RMS and the other six countries that the MAA for ILUVIEN was
approvable. To date, five of the seven countries, Austria, the United Kingdom,
Portugal, France and Germany have granted national licenses for ILUVIEN.
ILUVIEN has not been approved by the United States Food and Drug

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a
non-proprietary corticosteroid with demonstrated efficacy in the treatment of
ocular disease.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning
of the Private Securities Litigation Reform Act of 1995, regarding, among
other things, Alimera's commercial plans for ILUVIEN in Germany, the UK and
France. Such forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual results to differ
materially from those projected in its forward-looking statements. Meaningful
factors which could cause actual results to differ include, but are not
limited to, uncertainty as to Alimera's and Quintiles' ability to
commercialize, and market acceptance of, ILUVIEN in the EU, as well as other
factors discussed in the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections of
Alimera's Annual Report on Form 10-K for the year ended December 31, 2011 and
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, which
are on file with the Securities and Exchange Commission (SEC) and available on
the SEC's website at In addition to the risks described above and
in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the SEC, other unknown or
unpredictable factors also could affect Alimera's results. There can be no
assurance that the actual results or developments anticipated by Alimera will
be realized or, even if substantially realized, that they will have the
expected consequences to, or effects on, Alimera. Therefore, no assurance can
be given that the outcomes stated in such forward-looking statements and
estimates will be achieved.

All forward-looking statements contained in this press release are expressly
qualified by the cautionary statements contained or referred to herein.
Alimera cautions investors not to rely too heavily on the forward-looking
statements Alimera makes or that are made on its behalf. These forward-looking
statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such forward-looking
statements, whether as a result of new information, future events or

For press inquiries:            For investor inquiries:

Katie Brazel, Fleishman-Hillard John Mills, ICR

for Alimera Sciences            for Alimera Sciences

404-739-0150                    310-954-1105

SOURCE Alimera Sciences, Inc.

Press spacebar to pause and continue. Press esc to stop.